Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned an average recommendation of “Hold” from the sixteen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $21.43.

A number of research firms have recently issued reports on HIMS. TD Cowen reissued a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler reissued a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Needham & Company LLC began coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th.

Hims & Hers Health Stock Down 0.2 %

Shares of Hims & Hers Health stock opened at $30.02 on Monday. The stock’s fifty day moving average is $24.78 and its two-hundred day moving average is $20.98. Hims & Hers Health has a 52 week low of $8.09 and a 52 week high of $35.02. The company has a market capitalization of $6.56 billion, a PE ratio of 68.23 and a beta of 1.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the firm earned ($0.04) earnings per share. The business’s revenue was up 77.1% on a year-over-year basis. As a group, research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $22.20, for a total transaction of $166,500.00. Following the completion of the sale, the insider now directly owns 193,980 shares in the company, valued at approximately $4,306,356. The trade was a 3.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of the stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $16.50, for a total value of $38,593.50. Following the transaction, the insider now directly owns 176,952 shares of the company’s stock, valued at $2,919,708. The trade was a 1.30 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,067,315 shares of company stock valued at $25,435,489. Corporate insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently made changes to their positions in the company. Main Management ETF Advisors LLC purchased a new stake in Hims & Hers Health in the 3rd quarter valued at $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health in the third quarter valued at about $604,000. Carnegie Investment Counsel acquired a new stake in Hims & Hers Health during the third quarter worth about $5,531,000. Royce & Associates LP raised its holdings in Hims & Hers Health by 17.0% in the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after buying an additional 49,500 shares during the period. Finally, Versor Investments LP acquired a new stake in shares of Hims & Hers Health during the third quarter valued at about $634,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.